WHY BENLYSTA?

Dr. Don Thomas, Rheumatologist

Paid consultant to GSK at the time of filming.

  • TRANSCRIPT

    DR. THOMAS: My name is Doctor Don Thomas, I’ve been a rheumatologist for over 25 years, and I’m in private practice in Greenbelt, Maryland.

    ON-SCREEN TEXT: Dr. Don Thomas Rheumatologist
    Paid consultant to GSK at the time of filming.

    ON-SCREEN TEXT: “Why BENLYSTA?”

    DR. THOMAS:  When you take care of a systemic lupus patient, your goal is to always try to get that patient into remission as fast as you can. And by remission what I mean is...

    ON-SCREEN TEXT: “Get that patient into remission as fast as you can”

    DR. THOMAS:  ... I don’t like to see any active inflammation in their history, on my physical examination, nor in the laboratory tests that I do. So, if I put someone on a medication such as an antimalarial and if they’re not in remission within a few months, then I do consider BENLYSTA as one of my therapies.

    DR. THOMAS:  Number one, it’s one of the few FDA approved medications to treat systemic lupus. Number two, look at all the clinical trials that it’s passed and shown safety and efficacy. Number three, I really like the long-term extension trial which showed real world data showing a reduction in organ damage progression in patients, which I really like as well.

    ON-SCREEN TEXT:

    • FDA approved
    • Clinical trial efficacy and safety
    • Long-term extension trial

    DR. THOMAS: And then in addition, you don’t have to check additional labs above and beyond what you would typically need to check for with systemic lupus patients.

    DR. THOMAS: So, I think BENLYSTA is an important part of our armamentarium and medications in treating systemic lupus.

    ON-SCREEN TEXT: “BENLYSTA is an important part of our armamentarium”

    DR. THOMAS: Thank you for watching, and visit the BENLYSTA website for more information.

    ON-SCREEN TEXT: Visit the website

    ON-SCREEN TEXT: BENLYSTA is indicated for patients aged ≥5 with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving standard therapy and patients aged ≥18 with active lupus nephritis receiving standard therapy. BENLYSTA is not recommended in patients with severe active central nervous system lupus or in combination with other biologics.

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATION

    Previous anaphylaxis with BENLYSTA.

    Serious Infections: Serious and sometimes fatal infections have been reported, and occurred more frequently with BENLYSTA. Use caution in patients with severe or chronic infections, and consider interrupting therapy in patients with a new infection.

    Progressive Multifocal Leukoencephalopathy (PML): Cases of JC virus-associated PML resulting in neurological deficits, including fatal cases, have been reported. If PML is confirmed, consider stopping immunosuppressant therapy, including BENLYSTA.

    Please see additional Important Safety Information and full Prescribing Information, including Medication Guide, on the BENLYSTAHCP.com website.

    ON-SCREEN TEXT:
    BENLYSTA
    (belimumab)
    Intravenous Use 120 mg/vial
    Subcutaneous Use 200 mg/mL

    GSK Logo

    Trademarks are owned by or licensed to the GSK group of companies. |
    ©2022 GSK or licensor. BELVID210039 March 2022. Produced in USA.

You may also like

WHY BENLYSTA?

Dr. Alvin Wells,
Rheumatologist

BENLYSTA PATIENT CASE

Dr. Don Thomas,
Rheumatologist

JOIN US FOR
A LIVE WEBINAR

Paid consultants to GSK at the time of filming.